Clinical Trial Update: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers [Phase 1]

View source ↗

Summary

Aplitabart (IGM-8444) Phase 1a/1b study in solid tumors and various hematologic cancers was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chondrosarcoma
• Chronic Lymphocytic Leukemia
• Colorectal Cancer
• Non-hodgkin Lymphoma
• Sarcoma
• Small Lymphocytic Lymphoma
• Solid Tumor

Drugs mentioned

• Aplitabart (IGM-8444)

Snippet

Sponsor: IGM Biosciences, Inc. | Conditions: Solid Tumor, Colorectal Cancer | Phase 1 | Status: TERMINATED